SiBone (SIBN) Expected to Announce Quarterly Earnings on Monday

SiBone (NASDAQ:SIBN) is projected to announce its Q4 2025 results after the market closes on Monday, February 23rd. Analysts expect SiBone to post earnings of ($0.13) per share and revenue of $56.2610 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, February 23, 2026 at 4:30 PM ET.

SiBone Trading Up 0.1%

Shares of SIBN stock opened at $15.48 on Friday. The company has a quick ratio of 6.62, a current ratio of 7.97 and a debt-to-equity ratio of 0.21. The firm has a market cap of $671.68 million, a P/E ratio of -30.35 and a beta of 0.69. The company has a 50 day moving average of $17.84 and a 200-day moving average of $16.83. SiBone has a 12-month low of $12.49 and a 12-month high of $21.89.

Analysts Set New Price Targets

Several research firms have recently weighed in on SIBN. Morgan Stanley increased their price target on SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Needham & Company LLC increased their target price on shares of SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Truist Financial boosted their price target on shares of SiBone from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Finally, TD Cowen upgraded SiBone to a “strong-buy” rating in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.33.

Insiders Place Their Bets

In related news, SVP Michael A. Pisetsky sold 20,756 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $15.35, for a total transaction of $318,604.60. Following the transaction, the senior vice president directly owned 285,974 shares of the company’s stock, valued at approximately $4,389,700.90. This trade represents a 6.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Laura Francis sold 93,475 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $15.32, for a total value of $1,432,037.00. Following the completion of the sale, the chief executive officer directly owned 544,369 shares of the company’s stock, valued at approximately $8,339,733.08. This represents a 14.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 248,153 shares of company stock valued at $4,244,702 over the last three months. Corporate insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On SiBone

A number of hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC grew its holdings in shares of SiBone by 162.4% during the 4th quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock valued at $99,249,000 after purchasing an additional 3,115,001 shares during the last quarter. Vanguard Group Inc. boosted its position in SiBone by 1.7% during the third quarter. Vanguard Group Inc. now owns 2,489,989 shares of the company’s stock valued at $36,653,000 after buying an additional 41,449 shares during the period. Nuveen LLC grew its stake in shares of SiBone by 5.1% during the fourth quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock valued at $28,041,000 after buying an additional 69,229 shares during the last quarter. Cadian Capital Management LP grew its stake in shares of SiBone by 96.8% during the fourth quarter. Cadian Capital Management LP now owns 1,171,100 shares of the company’s stock valued at $23,094,000 after buying an additional 576,100 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of SiBone by 74.7% in the third quarter. Wellington Management Group LLP now owns 853,266 shares of the company’s stock worth $12,560,000 after buying an additional 364,897 shares during the period. 98.11% of the stock is currently owned by institutional investors.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.